Valeant Pharmaceuticals Intl (VRX) Rating Reiterated by Wells Fargo & Co

Wells Fargo & Co reissued their sell rating on shares of Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) in a report issued on Tuesday.

A number of other brokerages also recently commented on VRX. Zacks Investment Research downgraded Valeant Pharmaceuticals Intl from a hold rating to a sell rating in a research report on Thursday, October 12th. Piper Jaffray Companies set a $14.00 price target on Valeant Pharmaceuticals Intl and gave the company a sell rating in a research report on Sunday, October 22nd. Vetr raised Valeant Pharmaceuticals Intl from a strong sell rating to a sell rating and set a $12.46 price target for the company in a research report on Monday, September 18th. HC Wainwright reaffirmed a hold rating and set a $17.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Monday, September 18th. Finally, Deutsche Bank reissued a hold rating and issued a $18.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Monday, October 9th. Six analysts have rated the stock with a sell rating, nine have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $18.56.

Shares of Valeant Pharmaceuticals Intl (NYSE VRX) opened at $21.52 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84. The company has a market capitalization of $7,490.00, a P/E ratio of 5.52, a P/E/G ratio of 0.67 and a beta of -0.22. Valeant Pharmaceuticals Intl has a 52-week low of $8.31 and a 52-week high of $24.43.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $1.04 EPS for the quarter, beating the Zacks’ consensus estimate of $0.90 by $0.14. Valeant Pharmaceuticals Intl had a return on equity of 51.56% and a net margin of 15.35%. research analysts anticipate that Valeant Pharmaceuticals Intl will post 3.82 EPS for the current fiscal year.

In related news, Director John Paulson purchased 344,216 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was purchased at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the acquisition, the director now directly owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.87% of the company’s stock.

Several institutional investors have recently bought and sold shares of VRX. Dimensional Fund Advisors LP boosted its holdings in shares of Valeant Pharmaceuticals Intl by 327.6% in the third quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock worth $64,086,000 after acquiring an additional 3,426,410 shares during the period. Paulson & CO. Inc. boosted its holdings in shares of Valeant Pharmaceuticals Intl by 12.5% in the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock worth $377,372,000 after acquiring an additional 2,428,900 shares during the period. Renaissance Technologies LLC bought a new position in shares of Valeant Pharmaceuticals Intl in the second quarter worth $41,574,000. Beach Point Capital Management LP bought a new position in shares of Valeant Pharmaceuticals Intl in the third quarter worth $15,670,000. Finally, Gotham Asset Management LLC bought a new position in shares of Valeant Pharmaceuticals Intl in the second quarter worth $14,239,000. 49.45% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals Intl (VRX) Rating Reiterated by Wells Fargo & Co” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3147531/valeant-pharmaceuticals-intl-vrx-rating-reiterated-by-wells-fargo-co.html.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.